This content is machine translated Psoriasis: System therapies in everyday practice Current real-world data at a glance The better the efficacy of a systemic treatment, the higher the patient satisfaction, especially if the risk-benefit balance is favorable. This plausible correlation is impressively underpinned by current findings from...…
View Post 5 min This content is machine translated Moderate to severe atopic dermatitis Established and novel biologics – the therapeutic landscape is in flux Clinically, atopic dermatitis (AD) manifests itself through a polymorphic picture of efflorescences, with pruritus and xerosis in the foreground. In addition to the antibody therapies dupilumab, tralokinumab and lebrikizumab, which...…
View Post 6 min This content is machine translated Hidradenitis suppurativa: biologics reduce inflammatory processes Treatment recommendations depend on the severity and inflammatory activity Due to its phenotypic heterogeneity and multifactorial pathogenesis, hidradenitis suppurativa is a complex disease that can be difficult to treat. Fortunately, research has achieved significant breakthroughs in the recent past,...…
View Post 6 min This content is machine translated COPD: Tailor therapy to individual characteristics Risk of exacerbation correlates with the eosinophil count and other factors The severity of COPD is determined based on lung function values, exacerbation history and symptom burden. A triple combination with inhaled steroids (ICS) is recommended for patients with a high...…
View Post 6 min This content is machine translated Atopic dermatitis: proven therapeutic principles and innovations From healthcare research to precision medicine In Switzerland, around 20 percent of children are affected by atopic eczema, compared to 4-5 percent of adults. The disease burden of AD is considerable, which is also related to...…
View Post 11 min This content is machine translated COPD therapy Drug therapy – Update 2025 Chronic obstructive pulmonary disease (COPD) is a chronic inflammatory multisystem disease caused primarily by inhaled noxious substances in combination with environmental factors and genetic predispositions. The presence of such a...… CME-Test
View Post 2 min This content is machine translated TREATswitzerland Register Evaluation of system therapies for AD In addition to conventional immunosuppressants, several monoclonal antibodies (biologics) and Janus kinase inhibitors (JAK-i) are now approved for the systemic treatment of atopic dermatitis (AD) in Switzerland. The primary objective...…
View Post 11 min This content is machine translated COPD therapy Drug therapy – Update 2025 Chronic obstructive pulmonary disease ( COPD) is a chronic inflammatory multisystem disease caused primarily by inhaled noxious substances in combination with environmental factors and genetic predispositions. The presence of such...… CME-Test
View Post 8 min This content is machine translated Chronic inducible urticaria What has stayed the same, what has changed? Over the past decades, significant progress has been made in understanding the pathogenesis of chronic inducible urticaria (CIndU). Provocation tests continue to play an important role in confirming the diagnosis....…
View Post 8 min This content is machine translated Atopic dermatitis Implement the “minimal disease activity” concept Minimal disease activity (MDA) in atopic dermatitis (AD) is a concept that combines a treat-to-target therapeutic strategy with the principle of shared decision-making. The aim is to achieve a state...…
View Post 8 min This content is machine translated Psoriasis and PsA Biologics, oral peptide and trivalent nanobody – current results and trends Top-line results are available for both Icotrokinra and Sonelokimab, which attest to the great therapeutic potential of these innovative drug candidates. However, there is also extremely interesting new evidence from...…
